Compare Devon Energy Corp (DVN) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Devon Energy Corp vs TG Therapeutics Inc — how do they compare? Devon Energy Corp trades at $42.25 (market cap $50.44B), while TG Therapeutics Inc trades at $55.37 (market cap $8.41B). The key difference: Devon Energy Corp is far larger — about 6× TG Therapeutics Inc's market cap, and Devon Energy Corp pays a 2.38% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| DVN | TGTX | |
|---|---|---|
Market Cap | $50.44B | $8.41B |
Sector | Energy | Health |
52-Week High | $52.07 | $59.06 |
52-Week Low | $31.74 | $26.39 |
Enterprise Value | $57.22B | $8.65B |
Dividend Yield | 2.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Devon Energy (DVN) trades at $43.73, up 3.55% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed results, beating in Q3 and Q4 2025 but missing in Q1 2026, with Q2 results pending. The company maintains solid profitability with a 13.71% net margin and robust cash flow, supported by the Coterra acquisition targeting $2 billion in synergies by 2027. Debt-to-asset ratio improved to 26.54% in 2025, reflecting disciplined financial management.
Outlook remains positive with a consensus price target of $60.55, implying significant upside. Key opportunities include synergy realization and free cash flow growth, while risks involve oil price volatility and activist investor pressure for asset sales. The stock offers value with a P/E of 12.18, below sector averages, but investors should monitor Q2 earnings due August 4 for confirmation of growth trajectory.
TG Therapeutics (TGTX) trades at $55.01, down 3.69% today, with a bullish technical signal from moving averages and a consensus analyst rating of 'Buy' from 11 of 13 analysts. The company reported strong revenue growth to $616.29 million in 2025 and a net income of $447.18 million, though recent quarterly EPS misses and negative operating cash flow of -$24.77 million highlight volatility. Positive news includes Phase II trials for Briumvi in schizophrenia and Phase I success in myasthenia gravis, driving investor optimism.
Outlook: TGTX offers growth potential through pipeline expansion and robust sales guidance, but faces risks from clinical trial outcomes, cash flow challenges, and high valuation multiples. The stock's 70% year-to-date gain reflects high expectations, requiring careful monitoring of execution against earnings forecasts and regulatory milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
